Previous 10 | Next 10 |
Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q4 2019 Earnings Call Feb 13, 2020 , 5:00 p.m. ET Operator Continue reading
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2019 Earnings Conference Call February 13, 2020 05:00 PM ET Company Participants Danielle Keatley - Senior Director of Investor Relations Emil Kakkis - Chief Executive Officer & President Shalini Sharp - Chief Financial Officer Conf...
Ultragenyx (NASDAQ: RARE ) Q4 results : More news on: Ultragenyx Pharmaceutical Inc., Healthcare stocks news, Earnings news and commentary, , Read more ...
Ultragenyx Pharmaceutical (NASDAQ: RARE ): Q4 GAAP EPS of -$1.62 misses by $0.26 . More news on: Ultragenyx Pharmaceutical Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
2019 total revenue is $103.7 million; 2019 Crysvita ® (burosumab) revenue to Ultragenyx is $87.3 million 2020 Crysvita revenue in Ultragenyx territories guidance of $125 million to $140 million reaffirmed NOVATO, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut...
NOVATO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call on Thursday, Februa...
Investment Thesis Notwithstanding two commercialized products and a rich pipeline, the twelve-month share price decline for Ultragenyx Pharmaceutical Inc. ( RARE ) had approached ~6.5% by early 2020 compared to ~12.0% LTM (last-twelve-month) gain in the NBI (NASDAQ Biotechnology Index). ...
SARASOTA, Fla. and NOVATO, Calif., Jan. 15, 2020 (GLOBE NEWSWIRE) -- GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced that GeneTx...
The following slide deck was published by Ultragenyx Pharmaceutical Inc. in conjunction with this Read more ...
January 13, 2020 Palm Beach, FL –January 13, 2020 – Reports say that the global drug delivery across brain barrier market size is expected to reach USD $4.6 billion by 2026, according to a new report by Grand View Research, Inc. registering a CAGR of 30.2% over the f...
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 whi...
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the P...
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,11...